Anti-IL-1 agents were evaluated as well in Basaran et al. study in which eight pediatric FMF patients were considered refractory to colchicine because of the continuous severe attacks even after having the maximum colchicine dose (2 mg/day) (115). This evidence concerns the gene IL1B and familial Mediterranean fever.